Evidence map›Paper›PMID 32928232›Full record

ArticleMolecular cancer2020

Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA.

Min Kang, Bo Tang, Jixi Li, Ziyan Zhou, Kang Liu, Rensheng Wang, Ziyan Jiang, Fangfang Bi, David Patrick, Dongin Kim and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 96 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Eukaryotic Microproteins.Annual review of biochemistry · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Noncanonical microprotein regulation of immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  18. Microproteins unveiling new dimensions in cancer.Functional & integrative genomics · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Min KangThe First Affiliated Hospital of Guangxi Medical University, Nanning, 530022, Guangxi, China. km1019@163.com.
Bo TangThe First Affiliated Hospital of Guangxi Medical University, Nanning, 530022, Guangxi, China. dr_sntangbo@163.com.
Jixi LiThe First Affiliated Hospital of Guangxi Medical University, Nanning, 530022, Guangxi, China.
Ziyan ZhouThe First Affiliated Hospital of Guangxi Medical University, Nanning, 530022, Guangxi, China.
Kang LiuThe First Affiliated Hospital of Guangxi Medical University, Nanning, 530022, Guangxi, China.
Rensheng WangDepartment of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
Ziyan JiangDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT, 06510, USA.
Fangfang BiDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT, 06510, USA.
David PatrickDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT, 06510, USA.
Dongin KimDepartment of Pharmaceutical Sciences College of Pharmacy, University of Oklahoma, Oklahoma City, OK, 73117, USA.
Anirban K MitraIndiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, 46202, USA.
Yang Yang-HartwichDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT, 06510, USA. yang.yang@yale.edu.ORCID 0000-0002-0522-9053
Guangxi Medical University · CNYale University · USIndiana University Health · USSheng Jing Hospital · CNUniversity of Oklahoma · USYale Cancer Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

backgroundVery few proteins encoded by the presumed non-coding RNA transcripts have been identified. Their cellular functions remain largely unknown. This study identifies the tumor-suppressor function of a novel microprotein encoded by the precursor of miR-34a. It consists of 133 amino acid residues, thereby named as miPEP133 (pri-microRNA encoded peptide 133).

methodsWe overexpressed miPEP133 in nasopharyngeal carcinoma (NPC), ovarian cancer and cervical cancer cell lines to determine its effects on cell growth, apoptosis, migration, or invasion. Its impact on tumor growth was evaluated in a xenograft NPC model. Its prognostic value was analyzed using NPC clinical samples. We also conducted western blot, immunoprecipitation, mass spectrometry, confocal microscopy and flow cytometry to determine the underlying mechanisms of miPEP133 function and regulation.

resultsmiPEP133 was expressed in normal human colon, stomach, ovary, uterus and pharynx. It was downregulated in cancer cell lines and tumors. miPEP133 overexpression induced apoptosis in cancer cells and inhibited their migration and invasion. miPEP133 inhibited tumor growth in vivo. Low miPEP133 expression was an unfavorable prognostic marker associated with advanced metastatic NPC. Wild-type p53 but not mutant p53 induced miPEP133 expression. miPEP133 enhanced p53 transcriptional activation and miR-34a expression. miPEP133 localized in the mitochondria to interact with mitochondrial heat shock protein 70kD (HSPA9) and prevent HSPA9 from interacting with its binding partners, leading to the decrease of mitochondrial membrane potential and mitochondrial mass.

conclusionmiPEP133 is a tumor suppressor localized in the mitochondria. It is a potential prognostic marker and therapeutic target for multiple types of cancers.

Indexed as

AnimalsCell ProliferationFemaleFlow CytometryGene Expression Regulation, NeoplasticHeterograftsHSP70 Heat-Shock ProteinsHumansMiceMicroRNAsMitochondrial ProteinsNasopharyngeal CarcinomaOvarian NeoplasmsTumor Suppressor Protein p53Uterine Cervical NeoplasmsHSP70 Heat-Shock ProteinsHSPA9 protein, humanMicroRNAsMIRN34 microRNA, humanMitochondrial ProteinsTumor Suppressor Protein p53miPEP133miR-34aNasopharyngeal carcinomaPri-miRNA-encoded proteinTumor suppressor

Identifiers

PMID32928232
PMCPMC7489042
OpenAlexW3085604246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.